Alector Inc ALEC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Alector Announces Pricing of Underwritten Offering
-
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
-
Alector to Participate in Upcoming Healthcare Conferences
-
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $1.83
- Day Range
- $1.72–1.84
- 52-Week Range
- $1.09–2.76
- Bid/Ask
- $2.01 / $2.03
- Shares Outstanding
- 111.66M
- Market Cap
- $204.33M
- Volume/Avg
- 2M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 14.28
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 103
- Website
- https://www.alector.com
Valuation
|
Metric
|
ALEC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 14.28 |
Price/Cash Flow | — |
Price/Earnings
ALEC
Financial Strength
|
Metric
|
ALEC
|
|---|---|
Quick Ratio | 5.05 |
Current Ratio | 5.26 |
Interest Coverage | — |
Quick Ratio
ALEC
Profitability
|
Metric
|
ALEC
|
|---|---|
Return on Assets (Normalized) | −36.15% |
Return on Equity (Normalized) | −322.64% |
Return on Invested Capital (Normalized) | −151.41% |
Return on Assets
ALEC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|MyyWGD | LOCK|P<N% | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Fsq&!V | LOCK|^R>>C | $83B | |||
| Moderna Inc
MRNA
| LOCK|Xw&<$^ | LOCK|$P | $80B | |||
| argenx SE ADR
ARGX
| LOCK|Ql>NFRs | LOCK|#@ | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>b%k<?W | LOCK|SD^ | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>^T#!!B | LOCK|??W^ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|x#HXdHl | LOCK|^zg>S | $28B | |||
| Incyte Corp
INCY
| LOCK|^Vm?W# | LOCK|YgH | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|yTwn>v! | LOCK|<z | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|RY?%B@& | LOCK|>w | $14B |
United States